Contineum Therapeutics (CTNM) Equity Ratio (2023 - 2025)
Contineum Therapeutics has reported Equity Ratio over the past 3 years, most recently at 0.95 for Q3 2025.
- Quarterly results put Equity Ratio at 0.95 for Q3 2025, down 2.83% from a year ago — trailing twelve months through Sep 2025 was 0.95 (down 2.83% YoY), and the annual figure for FY2024 was 0.93, up 278.6%.
- Equity Ratio for Q3 2025 was 0.95 at Contineum Therapeutics, up from 0.94 in the prior quarter.
- Over the last five years, Equity Ratio for CTNM hit a ceiling of 0.98 in Q2 2024 and a floor of 0.61 in Q1 2024.
- Median Equity Ratio over the past 3 years was 0.93 (2025), compared with a mean of 0.57.
- Biggest five-year swings in Equity Ratio: skyrocketed 278.6% in 2024 and later fell 4.63% in 2025.
- Contineum Therapeutics' Equity Ratio stood at 0.52 in 2023, then skyrocketed by 278.6% to 0.93 in 2024, then increased by 1.62% to 0.95 in 2025.
- The last three reported values for Equity Ratio were 0.95 (Q3 2025), 0.94 (Q2 2025), and 0.93 (Q1 2025) per Business Quant data.